Experts said there should be comprehensive, cost-based price controls covering all oncology therapies, permanent statutory margin caps across distribution channels and full scrutiny of company assistance programmes.

See all 353 in Finance →

By

Leave a Reply

Your email address will not be published. Required fields are marked *